De-escalation of Prasugrel Results in Higher Percentage of Patients within Optimal Range of Platelet Reactivity: Analysis from the HOST-REDUCE-POLYTECH-ACS Trial
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.